Abstract
Background: Liver IR is a frequent clinical complication with high morbidity and mortality. The present study evaluated the possible protective effect of sodium hydrosulfide (NaHS), a H2S donor, in IR-induced hepatic injury and explored the mechanisms of actions of the investigated drug.
Methods: Male albino rats (200-230 g) were divided into the following groups: group 1:Sham-operated non treated rats, group 2: IR non treated rats, group 3: L-NNA + IR rats, group 4: NaHS + IR rats, group 5: L-NNA + NaHS + IR rats. Blood samples were collected for ALT determination. Liver tissue samples were used for the assessment of GPx, catalase, SOD, MDA, total nitrites and TNF- α. Parts from the liver were fixed in 10% formalin solution for histopathological examination and immunohistochemical examination of iNOS, eNOS and caspase-3.
Results: NaHS protected the liver against IR. This hepatoprotection was associated with normalization of antioxidant enzyme activity and decrease in hepatic MDA, TNF-α and expression of caspase- 3 and iNOS.
Conclusion: NaHS is hepatoprotective in IR injury. The hepatoprotective effects of NaHS are associated with antioxidant, anti-inflammatory and antiapoptotic effects. These effects are probably mediated via NO modulation.
Keywords: Ischemia reperfusion injury, sodium hydrosulfide, nitric oxide, hepatic surgery, liver cells, transplantation.
Graphical Abstract
[http://dx.doi.org/10.1016/j.ijsu.2016.05.050] [PMID: 27255130]
[http://dx.doi.org/10.3727/105221617X15042750874156] [PMID: 28893351]
[http://dx.doi.org/10.1007/978-1-4419-7107-4_26]
[http://dx.doi.org/10.1517/14656566.2016.1115015] [PMID: 26745388]
[http://dx.doi.org/10.1097/MD.0000000000013065] [PMID: 30383685]
[http://dx.doi.org/10.1038/labinvest.2008.73] [PMID: 18679378]
[http://dx.doi.org/10.1073/pnas.0705891104] [PMID: 17878306]
[http://dx.doi.org/10.1161/01.STR.0000204184.34946.41] [PMID: 16439695]
[PMID: 23290060]
[http://dx.doi.org/10.1371/journal.pone.0074422] [PMID: 24058562]
[http://dx.doi.org/10.1007/s00204-014-1263-1] [PMID: 24770553]
[http://dx.doi.org/10.3748/wjg.v23.i14.2505] [PMID: 28465634]
[http://dx.doi.org/10.3390/medicina55060304] [PMID: 31238587]
[http://dx.doi.org/10.1016/j.ejphar.2013.02.039] [PMID: 23499693]
[http://dx.doi.org/10.1016/j.ejphar.2007.06.010] [PMID: 17610873]
[http://dx.doi.org/10.3748/wjg.v16.i48.6079] [PMID: 21182222]
[http://dx.doi.org/10.1016/j.freeradbiomed.2007.04.026] [PMID: 17664129]
[http://dx.doi.org/10.5567/pharmacologia.2012.622.626]
[http://dx.doi.org/10.1124/mol.107.041079] [PMID: 18079278]
[http://dx.doi.org/10.1016/j.ejphar.2017.09.037] [PMID: 28966130]
[PMID: 9495876]
[http://dx.doi.org/10.1097/00007890-200102270-00008] [PMID: 11258432]
[http://dx.doi.org/10.1002/lt.21810] [PMID: 19790158]
[http://dx.doi.org/10.1007/s00595-014-1064-4] [PMID: 25362520]
[http://dx.doi.org/10.1111/j.1432-2277.2012.01514.x] [PMID: 22716165]
[http://dx.doi.org/10.1089/ars.2013.5604] [PMID: 24766279]
[http://dx.doi.org/10.1089/ars.2014.5901] [PMID: 24635322]
[http://dx.doi.org/10.1096/fj.02-0211hyp] [PMID: 12409322]
[http://dx.doi.org/10.1152/ajpheart.00013.2002] [PMID: 12124191]
[http://dx.doi.org/10.1096/fj.04-3583fje] [PMID: 15863703]
[http://dx.doi.org/10.1016/S0006-291X(03)00256-0] [PMID: 12646242]
[http://dx.doi.org/10.1016/j.yjmcc.2005.10.003] [PMID: 16325198]
[http://dx.doi.org/10.1152/ajpheart.00044.2012] [PMID: 22467307]
[http://dx.doi.org/10.1073/pnas.1321871111] [PMID: 24516168]